• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Production of SV40-derived vectors.

作者信息

Strayer David S, Mitchell Christine, Maier Dawn A, Nichols Carmen N

出版信息

Cold Spring Harb Protoc. 2010 Jun;2010(6):pdb.prot5436. doi: 10.1101/pdb.prot5436.

DOI:10.1101/pdb.prot5436
PMID:20516174
Abstract

Recombinant simian virus 40 (rSV40)-derived vectors are particularly useful for gene delivery to bone marrow progenitor cells and their differentiated derivatives, certain types of epithelial cells (e.g., hepatocytes), and central nervous system neurons and microglia. They integrate rapidly into cellular DNA to provide long-term gene expression in vitro and in vivo in both resting and dividing cells. Here we describe a protocol for production and purification of these vectors. These procedures require only packaging cells (e.g., COS-7) and circular vector genome DNA. Amplification involves repeated infection of packaging cells with vector produced by transfection. Cotransfection is not required in any step. Viruses are purified by centrifugation using discontinuous sucrose or cesium chloride (CsCl) gradients and resulting vectors are replication-incompetent and contain no detectable wild-type SV40 revertants. These approaches are simple, give reproducible results, and may be used to generate vectors that are deleted only for large T antigen (Tag), or for all SV40-coding sequences capable of carrying up to 5 kb of foreign DNA. These vectors are best applied to long-term expression of proteins normally encoded by mammalian cells or by viruses that infect mammalian cells, or of untranslated RNAs (e.g., RNA interference). The preparative approaches described facilitate application of these vectors and allow almost any laboratory to exploit their strengths for diverse gene delivery applications.

摘要

相似文献

1
Production of SV40-derived vectors.
Cold Spring Harb Protoc. 2010 Jun;2010(6):pdb.prot5436. doi: 10.1101/pdb.prot5436.
2
Titering replication-defective rSV40 vectors.
Cold Spring Harb Protoc. 2010 Jun;2010(6):pdb.prot5437. doi: 10.1101/pdb.prot5437.
3
Factors influencing the production of recombinant SV40 vectors.影响重组SV40载体产生的因素。
Mol Ther. 2004 Oct;10(4):780-91. doi: 10.1016/j.ymthe.2004.06.1014.
4
SV40-based gene therapy vectors: turning an adversary into a friend.基于SV40的基因治疗载体:化敌为友。
Curr Opin Mol Ther. 2000 Oct;2(5):570-8.
5
Efficient gene transfer to hematopoietic progenitor cells using SV40-derived vectors.使用源自SV40的载体将基因高效转移至造血祖细胞。
Gene Ther. 2000 May;7(10):886-95. doi: 10.1038/sj.gt.3301159.
6
Gene therapy using SV40-derived vectors: what does the future hold?使用源自SV40的载体进行基因治疗:未来会怎样?
J Cell Physiol. 1999 Dec;181(3):375-84. doi: 10.1002/(SICI)1097-4652(199912)181:3<375::AID-JCP1>3.0.CO;2-8.
7
A packaging system for SV40 vectors without viral coding sequences.一种用于无病毒编码序列的SV40载体的包装系统。
Anal Biochem. 1997 Dec 1;254(1):139-43. doi: 10.1006/abio.1997.2417.
8
Gene delivery to the liver using simian virus 40-derived vectors.
Semin Liver Dis. 1999;19(1):71-81. doi: 10.1055/s-2007-1007099.
9
Durability of transgene expression and vector integration: recombinant SV40-derived gene therapy vectors.转基因表达和载体整合的持久性:重组SV40衍生的基因治疗载体
Mol Ther. 2002 Aug;6(2):227-37. doi: 10.1006/mthe.2002.0657.
10
Foreign gene expression by human adenovirus type 5-based vectors studied using firefly luciferase and bacterial beta-galactosidase genes as reporters.使用萤火虫荧光素酶和细菌β-半乳糖苷酶基因作为报告基因,对基于5型人腺病毒载体的外源基因表达进行了研究。
Virology. 1995 Jun 20;210(1):226-30. doi: 10.1006/viro.1995.1337.

引用本文的文献

1
Cre Recombinase Mediates the Removal of Bacterial Backbone to Efficiently Generate rSV40.Cre重组酶介导细菌骨架的去除以高效生成重组猿猴病毒40(rSV40)。
Mol Ther Methods Clin Dev. 2018 Feb 27;9:225-233. doi: 10.1016/j.omtm.2018.02.010. eCollection 2018 Jun 15.